ANAPTYSBIO, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
ANAPTYSBIO, INC. (ANAB) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-03-03
- ANAPTYSBIO, INC. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $0.00.
- ANAPTYSBIO, INC. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ANAPTYSBIO, INC. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $7.34M.
- ANAPTYSBIO, INC. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-03 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-03 |
| 2023-12-31 | $7.34M 10-K · filed 2026-03-03 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2021-12-31 | $0.00 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |